Most Read Articles
Pearl Toh, 6 days ago
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 3 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
2 days ago
Weight loss medications that have received the Food and Drug Administration (FDA) approval appear to confer only modest positive benefits for cardiometabolic risk profile, according to a study.
3 days ago
The risk of stroke and subsequent mortality is significantly elevated in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), a recent study has shown.

Allopurinol protective against peripheral arterial disease in elderly

29 Jul 2017

Allopurinol may reduce the risk of peripheral arterial disease (PAD) in the elderly, with the protective effect of the drug increasing as duration of use increases, according to a retrospective cohort study from the US.

Using data from 5 percent of the Medicare beneficiaries (n=25,282) aged ≥65 years without PAD at baseline, researchers identified 26,985 episodes of new allopurinol exposure. Of the episodes, 3,167 (12 percent) ended in incident PAD.

Multivariable Cox regression analysis showed that allopurinol use reduced the risk of incident PAD by 12 percent (hazard ratio [HR], 0.88; 95 percent CI, 0.81 to 0.95). The risk was also associated with female gender (HR, 0.84; 0.78 to 0.90).

The extent of protection of allopurinol against PAD increased with longer durations of use. HRs for PAD were 0.88 (0.79 to 0.97) in the group with 181 days to 2 years of use and 0.75 (0.63 to 0.89) in those with >2 years of use.

Conversely, factors found to be associated with higher PAD risk included older age (age 75 to <85 and 85 years), higher Charlson index score and black race.

Sensitivity analyses controlling for cardiac conditions and medications returned similar results, with minimal to no attenuation of HRs.

A common manifestation of atherosclerosis, PAD is a major health problem, especially in the elderly. The disease affects approximately 8.5 million Americans, with the prevalence increasing with age. The mechanism by which allopurinol (commonly used to treat gout) reduces the risk of PAD potentially involves xanthine oxidase, which has long been suspected to play a role in cardiovascular disease. Xanthine oxidase inhibitors, such as allopurinol, demonstrate a dual mechanism of reduction of oxidative stress and urate lowering, which in turn reduce the risk of cardiovascular disease. [Lancet 2013;382:132940; Diabetic Med 2004;21:7249; J Rheumatol 2007;34:18827]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 3 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
2 days ago
Weight loss medications that have received the Food and Drug Administration (FDA) approval appear to confer only modest positive benefits for cardiometabolic risk profile, according to a study.
3 days ago
The risk of stroke and subsequent mortality is significantly elevated in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), a recent study has shown.